IS5275A - Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti - Google Patents

Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti

Info

Publication number
IS5275A
IS5275A IS5275A IS5275A IS5275A IS 5275 A IS5275 A IS 5275A IS 5275 A IS5275 A IS 5275A IS 5275 A IS5275 A IS 5275A IS 5275 A IS5275 A IS 5275A
Authority
IS
Iceland
Prior art keywords
treatment
growth hormone
insulin resistance
hormone secretion
secretion
Prior art date
Application number
IS5275A
Other languages
English (en)
Icelandic (is)
Inventor
Albert Carpino Philip
Kwok-Fung Chiu Charles
Allen Lefker Bruce
Codetta Pan Lydia
Lee Treadway Judith
Paul Zawistoski Michael
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS5275A publication Critical patent/IS5275A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS5275A 1997-06-25 1999-11-26 Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti IS5275A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Publications (1)

Publication Number Publication Date
IS5275A true IS5275A (is) 1999-11-26

Family

ID=21967444

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5275A IS5275A (is) 1997-06-25 1999-11-26 Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti

Country Status (40)

Country Link
US (3) US6448263B1 (instruction)
EP (1) EP1000085B1 (instruction)
JP (2) JP2000514099A (instruction)
KR (1) KR20010014224A (instruction)
CN (2) CN1530107A (instruction)
AP (1) AP1145A (instruction)
AR (1) AR012256A1 (instruction)
AT (1) ATE305477T1 (instruction)
AU (1) AU747510B2 (instruction)
BG (1) BG104008A (instruction)
BR (1) BR9810477A (instruction)
CA (1) CA2294464A1 (instruction)
CO (1) CO4950621A1 (instruction)
DE (1) DE69831745T2 (instruction)
DZ (1) DZ2539A1 (instruction)
EA (1) EA002089B1 (instruction)
EG (1) EG21712A (instruction)
ES (1) ES2248899T3 (instruction)
HN (1) HN1998000088A (instruction)
HR (1) HRP980361A2 (instruction)
HU (1) HUP0001922A3 (instruction)
ID (1) ID24345A (instruction)
IL (7) IL154111A0 (instruction)
IN (1) IN189724B (instruction)
IS (1) IS5275A (instruction)
MA (1) MA24581A1 (instruction)
NO (1) NO996205D0 (instruction)
NZ (1) NZ500655A (instruction)
OA (1) OA11242A (instruction)
PA (1) PA8452601A1 (instruction)
PE (1) PE105399A1 (instruction)
PL (1) PL337659A1 (instruction)
SK (1) SK175699A3 (instruction)
TN (1) TNSN98113A1 (instruction)
TR (1) TR199903257T2 (instruction)
TW (1) TW553943B (instruction)
UA (1) UA64751C2 (instruction)
WO (1) WO1998058949A1 (instruction)
YU (1) YU70199A (instruction)
ZA (1) ZA985546B (instruction)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
EP1159964B1 (en) 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
WO2004027064A2 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
AU2005319393B2 (en) * 2004-12-21 2010-09-02 Solenis Technologies Cayman, L.P. Reactive cationic resins for use as dry and wet strength agents in sulfite ion-containing papermaking systems
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
US20130296358A1 (en) 2012-05-03 2013-11-07 Ameet Vijay Ambarkhane 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
JP6337266B2 (ja) * 2013-05-28 2018-06-06 ラクオリア創薬株式会社 多形形態
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
ES2707124T3 (es) * 2014-08-05 2019-04-02 Raqualia Pharma Inc Derivados de serina como agonistas del receptor de grelina
KR20170078612A (ko) 2014-10-31 2017-07-07 라퀄리아 파마 인코포레이티드 그렐린 수용체 효능제로서 테트라히드로피라졸로피리딘 유도체
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN120265641A (zh) * 2023-04-21 2025-07-04 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
EP0669830A4 (en) 1992-11-06 1997-02-26 Merck & Co Inc SUBSTITUTED DIPEPTIDE ANALOGS PROMOTING THE RELEASE OF GROWTH HORMONE.
RO115804B1 (ro) 1992-12-11 2000-06-30 Merck & Co Inc Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
CA2175218A1 (en) 1993-11-09 1995-05-18 Gregori J. Morriello Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
ES2323159T3 (es) 1995-12-22 2009-07-07 Novo Nordisk A/S Compuestos con propiedades de liberacion de la hormona del crecimiento.
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
ATE356139T1 (de) * 1997-06-25 2007-03-15 Pfizer Dipeptidderivate zur förderung der sekretion von wachstumshormon
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)

Also Published As

Publication number Publication date
HK1028051A1 (en) 2001-02-02
ZA985546B (en) 2000-01-10
US6867202B1 (en) 2005-03-15
DE69831745T2 (de) 2006-08-31
EG21712A (en) 2002-02-27
JP3742643B2 (ja) 2006-02-08
IL154114A0 (en) 2003-07-31
AU747510B2 (en) 2002-05-16
UA64751C2 (uk) 2004-03-15
CN1259140A (zh) 2000-07-05
ATE305477T1 (de) 2005-10-15
DE69831745D1 (de) 2006-02-09
HN1998000088A (es) 1999-01-08
HUP0001922A3 (en) 2001-02-28
KR20010014224A (ko) 2001-02-26
IL156465A0 (en) 2004-01-04
TNSN98113A1 (fr) 2005-03-15
NO996205L (no) 1999-12-15
DZ2539A1 (fr) 2003-02-08
SK175699A3 (en) 2001-04-09
US6448263B1 (en) 2002-09-10
NZ500655A (en) 2002-02-01
AP1145A (en) 2003-02-14
IL133626A0 (en) 2001-04-30
NO996205D0 (no) 1999-12-15
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
IN189724B (instruction) 2003-04-19
WO1998058949A1 (en) 1998-12-30
MA24581A1 (fr) 1998-12-31
IL156465A (en) 2004-07-25
JP2000514099A (ja) 2000-10-24
AR012256A1 (es) 2000-09-27
IL154115A0 (en) 2003-07-31
TW553943B (en) 2003-09-21
CA2294464A1 (en) 1998-12-30
ID24345A (id) 2000-07-13
US6630487B2 (en) 2003-10-07
PL337659A1 (en) 2000-08-28
CN1152049C (zh) 2004-06-02
IL154116A0 (en) 2003-07-31
OA11242A (en) 2003-07-23
BR9810477A (pt) 2007-05-22
TR199903257T2 (xx) 2000-12-21
AP9801267A0 (en) 1998-06-30
EA002089B1 (ru) 2001-12-24
US20030100561A1 (en) 2003-05-29
HRP980361A2 (en) 1999-02-28
EA199901075A1 (ru) 2000-08-28
YU70199A (sh) 2003-01-31
EP1000085A1 (en) 2000-05-17
CN1530107A (zh) 2004-09-22
PE105399A1 (es) 1999-11-04
IL154111A0 (en) 2003-07-31
CO4950621A1 (es) 2000-09-01
BG104008A (en) 2000-07-31
EP1000085B1 (en) 2005-09-28
ES2248899T3 (es) 2006-03-16
AU7445698A (en) 1999-01-04
JP2005097261A (ja) 2005-04-14
PA8452601A1 (es) 2000-05-24

Similar Documents

Publication Publication Date Title
IS5275A (is) Meðhöndlun á insúlín viðnámi með vaxtarhormóna seyti
DE69531573D1 (de) Implantierbare rohrförmige Prothese mit Manschetten
DE69938295D1 (de) Kleinlumiges biologisches transplantat mit therapeutischer verabreichungsvorrichtung
DE69804533D1 (de) Ballonkatheter mit Impeller zur Blutförderung
FI963482A0 (fi) Menetelmä hematopoieesin stimuloimiseksi hemoglobiinilla
DE69711561D1 (de) Vorgefüllte Spritze
DE69733027D1 (de) Infusionsballonkatheter
DE69726584D1 (de) Einmalspritze
DE69507321D1 (de) Nadellose spritze
DE69504241D1 (de) Vorgefüllte Spritze
NO20001242L (no) April - et nytt protein med veksteffekter
DE69618028D1 (de) Medizinische zuleitung mit kompressionslumen
DE122004000049I1 (de) Neue Insulinderivate mit schnellem Wirkungseintritt.
DE69727968D1 (de) Ablations-katheter mit mehreren elektroden
NO973446L (no) Forbindelser med veksthormonfrigjörende egenskaper
PL338883A1 (en) Growth hormone secretion stimulating compounds
NO973438D0 (no) Insulinderivater med forhöyet sinkbinding
DE69810382D1 (de) Spritzennadel
DE69812588D1 (de) Medizinischer injektor
EP0688570A3 (de) Insulinspritze
NO975992D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
ZA987383B (en) Treatment of congestive heart failure with growth hormone secretagogues.
NO960485L (no) Selvdestruerende injeksjonsspröyte
ATE305790T1 (de) Behandlung der diabetes mit thiazolidindione, insulin sekretionförderer und biguanide
DE69904407D1 (de) Automatische Insulininjektionsspritze mit Arztmode